Drug Type Small molecule drug |
Synonyms LAMIVUDINE/STAVUDINE/NEVIRAPINE, STAVUDINE/LAMIVUDINE/NEVIRAPINE, D4T/3TC/NVP + [1] |
Target |
Action inhibitors |
Mechanism RT inhibitors(Viral reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC33H37N9O8S |
InChIKeyFEOBXHIFUYOHBP-KPTOQMEFSA-N |
CAS Registry811471-91-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | NDA/BLA | United States | 17 Nov 2006 |
Phase 3 | 34 | ixhhcnaecn = zopxtuncmt fkxbvdkuit (lxvznozbvz, obgxkqdihu - lfcefjjyhx) View more | - | 27 Aug 2018 | |||
ixhhcnaecn = zpsrlyhoau fkxbvdkuit (lxvznozbvz, sksxlearyq - ajalhqfkqh) View more | |||||||
Not Applicable | 103 | Triomune30 | amscxcwckp(tnenvmgbwp) = kbqrrbuyjl elwxssvywo (okmwlituqv ) | - | 01 Jan 2009 | ||
Not Applicable | - | kmqeqqfgdq(wyierawrbe) = Adverse events (rash, hepatitis, and nausea/vomiting) were found in 13 (14%) patients. pgoeycxijr (juswxxjxfz ) | - | 01 Jan 2004 |